ArticleCancer discovery2020
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.
0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed
7.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 139 citations in OpenAlex.
- Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.Nature communications · 2024Trial
- Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.Cancer discovery · 2021Trial
- Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design.Molecular cancer · 2026Review
- KRAS Inhibitor-Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones.Cancer research · 2026Article
- Cold and hot tumors: immunological determinants, cancer-immunity cycle dysregulation, and nanotechnology-driven therapeutic approaches.Molecular biomedicine · 2026Review
- Targeting cancer-intrinsic protein neddylation bypasses the loss of JAK/STAT signaling and overcomes acquired resistance to immunotherapy.Research square · 2026Article
- Cancer drug response and resistance: molecular mechanisms and combating strategies.Signal transduction and targeted therapy · 2026Review
- Adverse Early-Life Factors Associated with Clonal Hematopoiesis of Indeterminate Potential in Later Life.Biomedicines · 2026Article
- CXCL16-driven CD4Journal for immunotherapy of cancer · 2026Article
- Loss of JAK1 Function Causes G2-M Cell-Cycle Defects Vulnerable to KIF18A Inhibition.Cancer research · 2026Article
- Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming.Journal of hematology & oncology · 2026Review
- A longitudinal, multi-omic atlas reveals the emergence of a spatially organized immunosuppressive ecosystem in resistant melanoma.Cell reports. Medicine · 2026Article
- Inhibition of circulating glycocholic acid-regulated signaling potentiates immune checkpoint therapy in colorectal cancer.Nature communications · 2026Article
- Harnessing Inflammatory Monocytes to Overcome Resistance to Anti-PD-1 Immunotherapy.bioRxiv : the preprint server for biology · 2026Article
- A Darwinian Perspective on Tumor Evolution.International journal of biological sciences · 2026Review
- Cytotoxic CD4+ T cells in cancer: an emerging target for next-generation anticancer immunotherapy?Journal for immunotherapy of cancer · 2025Review
- The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee.Journal for immunotherapy of cancer · 2025Review
- Gold-siRNA supraclusters enhance the anti-tumor immune response of stereotactic ablative radiotherapy at primary and metastatic tumors.Nature biotechnology · 2025Article
- Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances.Journal of experimental & clinical cancer research : CR · 2025Review
- Improvement of the Anticancer Efficacy of PD-1/PD-L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies.MedComm · 2025Review
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 1 institution in 1 country.
Davis Y TorrejonDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.
Gabriel Abril-RodriguezDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.
Ameya S ChamphekarDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.
Jennifer TsoiDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.
Katie M CampbellDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.ORCID https://orcid.org/0000-0001-6491-4432
Anusha KalbasiDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
Giulia ParisiDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.
Jesse M ZaretskyDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.
Angel Garcia-DiazDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.
Cristina Puig-SausDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.
Gardenia Cheung-LauDivision of Surgical Oncology, Department of Surgery, University of California, Los Angeles, Los Angeles, California.
Thomas WohlwenderDivision of Surgical Oncology, Department of Surgery, University of California, Los Angeles, Los Angeles, California.
Paige KrystofinskiDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.ORCID https://orcid.org/0000-0001-8613-0954
Agustin Vega-CrespoDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.
Christopher M LeeDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.
Pau MascaroDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.
Catherine S GrassoDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.
Beata Berent-MaozDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.
Begoña Comin-AnduixDivision of Surgical Oncology, Department of Surgery, University of California, Los Angeles, Los Angeles, California.
Siwen Hu-LieskovanDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.
Antoni RibasDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California. aribas@mednet.ucla.edu.
University of California, Los Angeles · US
Funding
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5MVirology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 1991 to 2018
$39.9MUCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9MProject 3: Modeling and overcoming resistance to melanoma immunotherapyP01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORICEAU, GATIEN P · 2020 to 2024
$12.8MRepurposing of cancer therapeutics for treatment of patients with COVID-19 diseaseU54CA199090 · NCI · INSTITUTE FOR SYSTEMS BIOLOGY · PI HEATH, JAMES R., RIBAS, ANTONI · 2015 to 2020
$11.4MNext Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4MUCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3MTARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RIBAS, ANTONI · 2013 to 2017
$8.4MCindi Study: A Phase II Clinical Trial to Combine CD24Fc with Ipilimumab and Nivolumab to Decrease Immune Related Adverse Events (irAE)R44CA250889 · NCI · ONCOIMMUNE, INC. · PI HU-LIESKOVAN, SIWEN, ZHENG, PAN · 2020 to 2020
$397kNCI NIH HHS P01 CA168585NCI NIH HHS P01 CA244118NCI NIH HHS P30 CA016042NCI NIH HHS R35 CA197633NCI NIH HHS R44 CA250889NCI NIH HHS T32 CA009120NCI NIH HHS U54 CA199090NIAID NIH HHS P30 AI028697NIGMS NIH HHS T32 GM008042
Abstract
Mechanism-based strategies to overcome resistance to PD-1 blockade therapy are urgently needed. We developed genetic acquired resistant models of
Indexed as
Animalsbeta 2-MicroglobulinCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell Line, TumorCell ProliferationDrug Resistance, NeoplasmHumansInterferonsInterleukin-2Janus Kinase 1Janus Kinase 2Killer Cells, NaturalLoss of Function MutationMice, Inbred C57BLNeoplasmsbempegaldesleukinbeta 2-MicroglobulinInterferonsInterleukin-2Janus Kinase 1Janus Kinase 2Polyethylene GlycolsProgrammed Cell Death 1 ReceptorToll-Like Receptor 9
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.